Ralf Schmid
Critic · DISC type CRalf Schmid is a senior international life science executive with over 20 years of experience in finance, M&A, and licensing. As the CFO of F2G Ltd. , he leverages his expertise from previous roles at Nabriva Therapeutics, where he was instrumental in their Nasdaq IPO, and Sandoz. He holds a masters in finance and economics from Otto-Friedrich-Universität Bamberg.
Originally from Germany and now an Austrian resident, Ralf maintains a keen interest in the broader European life sciences community. He follows organizations like LISAvienna, a network supporting the life sciences hub in Vienna, where he was previously based with Nabriva Therapeutics AG.
Unique fact: He played a pivotal role in leading the successful spin-off of Nabriva Therapeutics from Sandoz and its subsequent public listing on Nasdaq.
Read the full overview →How Ralf shows up
Unless the value is proven by data, they are unlikely to value fancy features. They enjoy working alone and do not rely on others very often. They prefer to do logical analysis and value evidence over emotions.
Topics Ralf cares about
Work history
Media appearances
DISC profile (public)
Calculativeness (C)
Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.
More profiles
Discover additional public profiles from our index.
Search more profiles
Looking for someone else? Search here for anyone.